Similar articles

• Erythromycin-resistant group A streptococci.

  Shulman ST, Tanz R, Kabat W. Shulman ST, et al. N Engl J Med. 2002 Aug 22;347(8):614-5; author reply 614-5. N Engl J Med. 2002. PMID: 12195586 No abstract available.
• Susceptibility of Streptococcus pyogenes to two macrolides in northern Israel.

  Sakran W, Raz R, Chazan B, Koren A, Colodner R. Sakran W, et al. Int J Antimicrob Agents. 2004 May;23(5):517-9. doi: 10.1016/j.ijantimicag.2003.09.025. Int J Antimicrob Agents. 2004. PMID: 15120735
• [Macrolides in the treatment of streptococcal pharyngitis: not all effective].

  Alós JI. Alós JI. Med Clin (Barc). 1999 Jan 16;112(1):18-9. Med Clin (Barc). 1999. PMID: 10027181 Spanish. No abstract available.
• [Streptococcal pharyngitis].

  Romero J, Betriu C. Romero J, et al. Enferm Infecc Microbiol Clin. 1995 Dec;13(10):611-27. Enferm Infecc Microbiol Clin. 1995. PMID: 8808478 Review. Spanish. No abstract available.
• Management of streptococcal pharyngitis.

  Klein JO. Klein JO. Pediatr Infect Dis J. 1994 Jun;13(6):572-5. doi: 10.1097/00006454-199406000-00035. Pediatr Infect Dis J. 1994. PMID: 8078757 Review. No abstract available.